Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study

被引：0
|
作者：
Vermersch, P.
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. Soelberg
Kurukulasuriya, N.
Viglietta, V.
Chang, P.
Papasouliotis, O.
Greenberg, S.
机构：
[1] Univ Lille Nord de France, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Univ Med & Dent, Newark, NJ USA
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Univ Miami, Miami, FL USA
[6] Univ Erlangen Nurnberg, Bamberg, Germany
[7] Copenhagen Univ Hosp, Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [31] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Giovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [32] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    Giovannoni, G.
    SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
  • [33] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
  • [34] Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Hamlett, Anthony
    Scaramozza, Matthew
    Lachenal, Nathalie
    NEUROLOGY, 2013, 80
  • [35] Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data
    Benedict, R. H.
    Comi, G.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuenzel, T.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 392 - 393
  • [36] Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
    de Stefano, N.
    Giorgio, A.
    Battaglini, M.
    Giovannoni, G.
    Hicking, C.
    Dangond, F.
    Sormani, M. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 532 - 532
  • [37] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [38] MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S114 - S114
  • [39] Clinical outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S114 - S114
  • [40] Clinical efficacy of cladribine tablet therapy in patients with relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S9 - S10
12345